Studying hormone and metabolism changes in pulmonary arterial hypertension
Observes how hormones and metabolism relate to pulmonary arterial hypertension, a lung blood pressure disease.
Plain-language title generated from the registry record
Registry title: Hormonal, Metabolic, and Signaling Interactions in PAH
Key facts
- Where
- Nashville, United StatesSee the site
Where in United States
- Vanderbilt University Medical CenterNashville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vanderbilt University Medical Center
- Trial code
- NCT01884051
- Record updated
- 25 September 2026
- Original description
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.Read full original descriptionShow less
Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
Inclusion: Project 1; Inclusion:; Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons; Age 0-90, age 12-90 for skin biopsy; Exclusion:; Other diagnosis; Age greater than 90, age less than 12 or greater than 90 for skin biopsy; Project 2; Inclusion:; Diagnosis of IPAH, HPAH, or APAH, family members of affected persons; 0-90; Subjects with reasonably easy access to clinic for blood collection and other testing; Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing; Exclusion:; Other diagnosis; 0-90; Subjects with difficulty reaching clinic for blood collection and other testing; Subjects unable to tolerate fasting state; Project 3; Inclusion:; Diagnosis of IPAH, HPAH, or APAH, family members of affected persons; 7-90; Exclusion:; Other diagnosis; Age less than 7 or greater than 90; -.
Exclusion: -.